405TiP - A Phase II Study of Albumin-Bound Paclitaxel Combined with Epirubicin and Cyclophosphamide as Neo-Adjuvant Therapy in Breast Cancer Women

Abstract

ABSTRACT Purpose To observe whether the efficacy and safety of Albumin-Bound Paclitaxel has advantage over Cremophor-Formulated Paclitaxel as neo-adjuvant therapy in breast cancer Patients and methods Twenty-six breast cancer patients were enrolled into Albumin-Bound Paclitaxel group. Albumin-Bound Paclitaxel 260mg/m2, Epirubicin 60 mg/m2, Cyclophosphamide 500mg/m2 was administrated as neo-adjuvant therapy. Twenty-six patients who were treated with Cremophor-Formulated Paclitaxel 175mg/m2, Epirubicin 60 mg/m2, Cyclophosphamide 500mg/m2 as the control group. The objective observation include the pathologic complete response rates, clinical response rates, safety and toxicity. The PI3K, pAKT, mTOR, BAD protein were examined before and after chemotherapy in two groups. Results 34.6% patients (9/26) in Albumin-Bound Paclitaxel group achieved a clinical complete response, this rate was 11.5% higher than control group which rate was 23.1%(6/26). 15.4% patients (4/26) in Albumin-Bound Paclitaxel group achieved a pathologic complete response, this rate was 11.6% higher than control group which rate was 3.8%(1/26). None patients (0/26) in Albumin-Bound Paclitaxel group occurs neutropenia but 15.4% patients (4/26) in control group occurs neutropenia during chemotherapy. All patients have normal left ventricular ejection fraction range (LVEF > 50%) before and after therapy. The positive rate of PI3K, mTOR, pAKT expression decreased 45.6%,42.5%,41.1% respectively in Albumin-Bound Paclitaxel group after chemotherapy and the control group decreased 13.2%,14.1%,10.1%. The positive rate of BAD expression increased 21.6% in Albumin-Bound Paclitaxel group after chemotherapy and the control group only increased 6.2%. Conclusion Albumin-Bound Paclitaxel has advantage in clinical response rate over Cremophor-Formulated Paclitaxel in breast cancer. Albumin-Bound Paclitaxel has no more additional adverse events than Cremophor-Formulated Paclitaxel. Albumin-Bound Paclitaxel has lower incidence of neutropenia than Cremophor-Formulated Paclitaxel. Albumin-Bound Paclitaxel decrease the expression of PI3K, pAKT, mTOR protein and increase the expression of BAD protein more significantly than Cremophor-Formulated Paclitaxel after chemotherapy Disclosure All authors have declared no conflicts of interest.